Trial Profile
A Phase I, Multicenter, Open-label, Single-sequence Drug-drug Interaction Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Capmatinib (Primary) ; Digoxin; Rosuvastatin
- Indications Adenocarcinoma; Bladder cancer; Colon cancer; Intestinal cancer; Liver cancer; Lung cancer; Malignant melanoma; Mouth neoplasm; Oesophageal cancer; Pancreatic cancer; Peritoneal cancer; Rectal cancer; Renal cancer; Solid tumours; Uterine cancer
- Focus Pharmacokinetics
- Sponsors Novartis; Novartis Pharmaceuticals
- 09 Dec 2020 Results published in the British Journal of Clinical Pharmacology
- 26 May 2017 Status changed from active, no longer recruiting to completed.
- 04 Apr 2017 Status changed from recruiting to active, no longer recruiting.